AI-generated research brief — verify at source
SB012 DNAzyme Enema Misses Primary Endpoint in Active Ulcerative Colitis Trial
A phase 2a randomized controlled trial found that four weeks of SB012 enema therapy did not produce a statistically significant reduction in Total Mayo Score compared to placebo in patients with moderately-to-severely active ulcerative colitis (treatment difference P = 0.286). A potentially meaningful signal emerged in the subgroup not using glucocorticoids, where SB012 was associated with a 2.2-point greater improvement over placebo (95% CI: −4.1 to −0.3; P = 0.027), though this finding is exploratory given the very small sample size.
What Was Studied
This trial evaluated whether SB012 — an enema formulation delivering the DNAzyme hgd40, which specifically inactivates GATA3 messenger RNA — could serve as an effective induction therapy for patients with moderately-to-severely active ulcerative colitis. The primary outcome was the change in Total Mayo Score from baseline to week 4 in the SB012 group relative to placebo, with GATA3 targeted on the basis of its implicated role in driving mucosal inflammation in UC.
How It Was Studied
This was a randomized, double-blind, placebo-controlled, multicenter phase 2a induction trial enrolling 20 patients with moderately-to-severely active ulcerative colitis. Participants were allocated in a 2:1 ratio to receive either SB012 enema (225 mg hgd40) or a matched placebo enema administered once daily for four weeks. Endoscopic outcomes were also assessed at weeks 4 and 8, extending observation beyond the primary treatment window. The unequal randomization ratio reflects the early-phase, primarily safety-oriented design of the study.
What Was Observed
- Primary endpoint not met: The difference in Total Mayo Score change between the SB012 and placebo groups at week 4 did not reach statistical significance (P = 0.286), meaning the trial failed to demonstrate a meaningful treatment benefit over placebo in the overall population.
- Within-group improvement in SB012 arm: Among patients receiving SB012, the median Total Mayo Score fell from 9.0 (interquartile range 6.5–10) at baseline to 7.0 (4.0–8.5) at week 4 — a statistically significant within-group reduction (P = 0.004) — while no comparable change was seen in the placebo group. This within-group signal does not, however, constitute evidence of superiority over placebo.
- Glucocorticoid-free subgroup showed a differential response: In patients not receiving concomitant glucocorticoids, SB012 was associated with a 2.2-point greater reduction in Total Mayo Score compared to placebo (95% CI: −4.1 to −0.3; P = 0.027). No improvement relative to placebo was detected in patients who were using corticosteroids concurrently, suggesting possible interaction between treatment and baseline corticosteroid use.
- Endoscopic outcomes showed no group differences: Endoscopic improvement rates were nearly identical between arms at both assessed timepoints — 17% in the SB012 group versus 17% in the placebo group at week 4 (P = 1.0), and 57% versus 50% at week 8 (P = 1.0) — indicating no detectable benefit on mucosal healing endpoints.
Why This Matters
GATA3 has been specifically implicated in the mucosal pathogenesis of ulcerative colitis, and SB012 represents an attempt to selectively silence this transcription factor using a topically delivered DNAzyme — a mechanistically distinct approach from current pharmacological treatments. The tolerability of the SB012 enema across the study period suggests that topical GATA3-targeting is feasible from a safety standpoint. The differential response observed in patients not on glucocorticoids raises the hypothesis that corticosteroid co-treatment may confound or interfere with the agent’s activity, a question that would need to be addressed in future, appropriately designed trials.
How to Read This Result
Given the very small sample size (N = 20), the 2:1 randomization imbalance, and the exploratory nature of the subgroup analysis, these findings are insufficient to draw firm conclusions about the efficacy of SB012, and the nominally significant result in glucocorticoid-free patients should be interpreted with considerable caution.
Limitations
The most critical constraint is the very small overall sample (N = 20), which renders the trial substantially underpowered to detect clinically meaningful differences or to support reliable subgroup analyses. As a phase 2a study, it was designed primarily around safety and feasibility rather than definitive efficacy. Concomitant glucocorticoid use was unevenly distributed and confounded interpretation of the primary endpoint. All subgroup findings — including the apparently positive result in glucocorticoid-free patients — are exploratory and hypothesis-generating only, not confirmatory.